# Appeal-Outcome Feedback Loop into Guideline Language

**Niche:** [[niches/acupuncture-practices/conservative-care-guideline-publishers/profile|Conservative-Care Treatment Guideline Publishers]]
**Industry:** [[industries/acupuncture-practices|Acupuncture Practices]]
**Type:** Build (Greenfield Opportunity)
**One-liner:** An engine that joins every authorization denial and appeal reversal back to the specific guideline clause that produced it, turning the downstream consequences of editorial wording into evidence the writers can actually see.
**Tags:** #gradient-boosting #logistic-regression #feature-engineering #evaluation-metrics #cross-validation #causal-inference #change-point-detection #data-integration #compliance #revenue-impact

## The Problem
A guideline publisher's writers make thousands of small wording decisions a year — a visit ceiling moves from twelve to eight, a documentation requirement gains the word "objective," an indication list drops a diagnosis code. Each one propagates into millions of authorization decisions at licensee payers. Some produce exactly the intended effect. Others produce a denial pattern nobody anticipated, get appealed, and get reversed at independent review at a rate that quietly signals the clause is wrong. None of this comes back. The publisher ships an edition and learns how it performed only through anecdote: a licensee's medical director mentions friction on a call, a state regulator asks about a denial pattern, a plaintiff's firm cites the clause in litigation. The single richest signal about guideline quality — what happened when it was applied at scale — sits in licensee systems and never reaches the people writing the next edition.

## Why Nobody Has Built This
The join does not exist. Authorization decisions live in each licensee's utilization management platform, keyed to their own case identifiers; appeals and independent review outcomes live in yet another system, often at a third-party IRO; and the guideline is referenced in those records as a version string and a section number at best, frequently as free text a reviewer typed. Reconstructing which clause drove which denial means matching across three systems that share no key, at organizations that have no contractual obligation to share any of it. There is also a genuine hesitancy: a publisher that can measure which of its clauses generate reversals is creating a discoverable record about its own product, and the safe institutional answer has been not to look.

## What to Build
An engine that gives every guideline clause a durable identifier that survives edition changes, and a licensee-side capture layer that records which clause was applied to each determination and what happened afterward — approved, denied, appealed, upheld, reversed, and on what ground. Data returns in aggregate and de-identified, so no licensee exposes case detail and the publisher never holds protected health information. On top of that record, two capabilities that do not exist today. Retrospective: which clauses generate reversal rates far above baseline, which show sharp behavior changes after an edit, which behave differently across states in ways that suggest a regulatory conflict rather than a clinical one. Prospective: a proposed edit is scored against the historical response of structurally similar clauses before it ships, so the editorial board sees the likely field effect while the wording is still changeable.

## Target Customer
VPs of clinical content and chief medical officers at guideline publishers running 100-400 clinical staff, and the medical directors at licensee payers and state workers' compensation systems who currently absorb the consequences of guideline wording with no way to feed anything back.

## Impact If Built
Converts the licensee network from a distribution channel into an evidence-generating instrument, which is the one asset a competing publisher structurally cannot replicate without the same installed base. Editorial quality becomes measurable against field outcomes rather than against internal review. And the ability to tell a prospective licensee how a guideline actually performs in adjudication — with numbers — changes the sales conversation from clinical credentials to demonstrated effect.
